Furthermore, the phase III IMpower010 trial reported the significant advantages of adjuvant atezolizumab, a programmed death-ligand 1 (PD-L1) antibody, in patients in whom ≥1% of tumor cells were positive for PD-L1 (3, 4). This evidence concerns the gene CD274 and neoplasm.